Inozyme Pharma
INZY
INZY was delisted on the 30th of June, 2025.
37 hedge funds and large institutions have $30.5M invested in Inozyme Pharma in 2022 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 11 increasing their positions, 10 reducing their positions, and 7 closing their positions.
10% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 10
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4.86% less ownership
Funds ownership: 76.81% → 71.95% (-4.9%)
5% less funds holding
Funds holding: 39 → 37 (-2)
14% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 7
63% less capital invested
Capital invested by funds: $82.7M → $30.5M (-$52.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$880K |
| 2 |
AAA
Affinity Asset Advisors
New York
|
+$874K |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$786K |
| 4 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$487K |
| 5 |
CA
CHI Advisors
New York
|
+$365K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$5.6M |
| 2 |
Janus Henderson Group
London,
|
-$1.91M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.63M |
| 4 |
MB
MPM BioImpact
Boston,
Massachusetts
|
-$753K |
| 5 |
Walleye Capital
New York
|
-$315K |
INZY Hedge Fund Activity: Q4 2022 in Review
37 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Inozyme Pharma (INZY) for Q4 2022, worth a combined $30.5M — down 63% from $82.7M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of INZY and 6 opened new positions — a net loss of 1 holder — while 10 trimmed existing stakes and 11 added.
The largest buyer was Adage Capital Partners, adding an estimated $880K. The largest seller was Deerfield Management, exiting entirely with an estimated $5.6M sold.
- 37 institutional investors held Inozyme Pharma (INZY) as of Q4 2022, down from 39 in Q3 2022.
- Funds reported $30.5M of Inozyme Pharma stock for Q4 2022, down 63% quarter-over-quarter.
- 6 funds opened new Inozyme Pharma positions in Q4 2022 and 7 closed out, a net change of -1 holder.
- The largest Inozyme Pharma buyer in Q4 2022 was Adage Capital Partners, an estimated $880K added.
- The largest Inozyme Pharma seller in Q4 2022 was Deerfield Management, an estimated $5.6M sold.
Based on aggregated 13F filings for Q4 2022.